

Yair Lotan

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/331183/publications.pdf](https://exaly.com/author-pdf/331183/publications.pdf)

Version: 2025-02-01

616

PR articles

36,431

PR citations

2854

89

PR h-index

2992

185

g-index

692

documents

42794

doc citations

2615

98

h-index

37254

citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. <i>BJU International</i> , 2025, 135, 260-268.	3.2	23
2	The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2025, 135, 88-94.	3.2	4
3	Prognostic models for predicting oncological outcomes after surgical resection of a nonmetastatic renal cancer: A critical review of current literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2025, 43, 380-389.	1.8	2
4	A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. <i>BJU International</i> , 2025, 135, 648-656.	3.2	2
5	Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. <i>European Urology Open Science</i> , 2025, 73, 24-30.	0.6	3
6	Cumulative smoking exposure impacts oncologic outcomes of upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2025, 43, 330.e19-330.e29.	1.8	2
7	Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies. , 2025, 32, 29-36.		0
8	Feasibility and outcomes of interventions to reduce cystoscopy discomfort: a multi-site pilot study. <i>BJU International</i> , 2025, 136, 507-514.	3.2	1
9	First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2024, 42, 20.e17-20.e23.	1.8	6
10	Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. <i>BJU International</i> , 2024, 133, 341-350.	3.2	15
11	Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2024, 42, 223-228.	1.8	3
12	The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. <i>Nature Communications</i> , 2024, 15, .	13.7	25
13	Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2024, 42, 177.e5-177.e14.	1.8	4
14	Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance" A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy. <i>European Urology Open Science</i> , 2024, 63, 19-30.	0.6	12
15	Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry. <i>Cancers</i> , 2024, 16, 1268.	3.8	0
16	The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. <i>BJU International</i> , 2024, 134, 119-127.	3.2	4
17	Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. <i>JAMA Oncology</i> , 2024, 10, 726.	14.4	40
18	Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. <i>Journal of Urology</i> , 2024, 212, 74-86.	4.2	63

#	ARTICLE	IF	CITATIONS
19	Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy. <i>Bladder Cancer</i> , 2024, 10, 119-132.	0.5	6
20	An evaluation of nadofaragene firadenovec-vnvcg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2024, 24, 415-423.	3.0	0
21	Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Société Internationale D'urologie Journal</i> , 2024, 5, 202-213.	0.2	1
22	Mitochondrial complex I promotes kidney cancer metastasis. <i>Nature</i> , 2024, 633, 923-931.	37.9	77
23	Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. <i>European Urology</i> , 2024, 86, 516-527.	2.1	32
24	Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. <i>JCI Insight</i> , 2024, 9, .	5.4	13
25	North American study and meta-analysis evaluating performance of Bladder EpiCheck [®] , a FDA cleared test, in non-muscle invasive bladder cancer recurrence. <i>Bladder Cancer</i> , 2024, 10, 278-289.	0.5	3
26	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	1.0	1
27	A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines. <i>European Urology Oncology</i> , 2023, 6, 183-189.	5.8	5
28	Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 53-67.	2.0	12
29	Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 109.e9-109.e14.	1.8	3
30	Early experience with UGN-101 for the treatment of upper tract urothelial cancer – A multicenter evaluation of practice patterns and outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 147.e15-147.e21.	1.8	10
31	Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 148.e17-148.e24.	1.8	6
32	Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer. <i>European Urology Open Science</i> , 2023, 51, 39-46.	0.6	5
33	Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. <i>BJU International</i> , 2023, 132, 170-180.	3.2	54
34	Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging. <i>BMC Medicine</i> , 2023, 21, .	7.1	18
35	Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction. <i>Clinical Cancer Research</i> , 2023, 29, 3668-3680.	6.8	18
36	Commentary on Novitas LCD. <i>Bladder Cancer</i> , 2023, 9, 305-312.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 9.e19-9.e27.	1.8	15
38	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 207, 70-76.	4.2	25
39	Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System. <i>Journal of Urology</i> , 2022, 207, 52-60.	4.2	11
40	The early impact of medicaid expansion on urologic malignancies in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 103.e1-103.e8.	1.8	4
41	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. <i>Journal of Urology</i> , 2022, 207, 534-540.	4.2	11
42	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2022, 207, 541-550.	4.2	54
43	Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry. <i>BJU International</i> , 2022, 130, 62-67.	3.2	7
44	SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 290-301.	1.5	23
45	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.3	3
46	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	3.5	6
47	Corrigendum to "Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis" [Eur Urol Oncol 2021;4:927-42]. <i>European Urology Oncology</i> , 2022, 5, 480-481.	5.8	4
48	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	2.6	3
49	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718.	5.8	71
50	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	1.8	33
51	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	2.3	8
52	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. <i>European Urology</i> , 2022, 81, 223-228.	2.1	22
53	Prognostic impact of insulin-like growth factor and its binding proteins, insulin-like growth factor binding protein 2 and 3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, 29, 676-683.	1.6	4
54	Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 201.e1-201.e7.	1.8	8

#	ARTICLE	IF	CITATIONS
55	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46.	2.1	73
56	Progress in the development of tissue-based biomarkers for urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 605-619.	2.5	1
57	Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. <i>Journal of Endourology</i> , 2022, 36, 1070-1076.	2.8	8
58	Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration. <i>Bladder Cancer</i> , 2022, 8, 303-314.	0.5	4
59	Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer. <i>Metabolites</i> , 2022, 12, 544.	3.4	11
60	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e1-382.e6.	1.8	5
61	Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 408.e9-408.e18.	1.8	17
62	A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. <i>Frontiers in Oncology</i> , 2022, 12, .	2.6	20
63	Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 2707-2715.	2.3	5
64	Epidemiology, Screening, and Prevention of Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 628-639.	5.8	266
65	Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis. <i>World Journal of Urology</i> , 2022, 41, 471-476.	2.3	9
66	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. <i>BJU International</i> , 2021, 128, 57-64.	3.2	20
67	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	3.2	12
68	Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. <i>BJU International</i> , 2021, 128, 168-177.	3.2	18
69	Robotic Nephroureterectomy vs Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. <i>Journal of Endourology</i> , 2021, 35, 312-318.	2.8	29
70	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	3.2	16
71	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	3.2	13
72	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , The, 2021, 22, 107-117.	27.4	368

#	ARTICLE	IF	CITATIONS
73	Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. <i>European Urology Oncology</i> , 2021, 4, 93-101.	5.8	37
74	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 617-625.	3.2	22
75	Decision Analysis Model Comparing Cost of IsoPSA vs Repeat Biopsy for Detection of Clinically Significant Prostate Cancer in Men with Previous Negative Findings on Biopsy. <i>Urology Practice</i> , 2021, 8, 40-46.	1.3	3
76	Bladder Cancer Tissue-Based Biomarkers. <i>Société Internationale D'urologie Journal</i> , 2021, 2, 53-71.	0.2	1
77	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144.	4.2	44
78	Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. <i>Bladder Cancer</i> , 2021, 7, 23-31.	0.5	3
79	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 769-779.	4.2	70
80	MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, .	2.6	14
81	Simple Nephrectomy in a Tertiary Care Safety Net Hospital—Patient Characteristics, Causes, Cost, and Renal Function Implications. <i>Urology</i> , 2021, 149, 98-102.	1.4	2
82	Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 787.e1-787.e7.	1.8	7
83	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 71, 85-95.	4.6	12
84	Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert) for bladder cancer. <i>BJU International</i> , 2021, 128, 713-721.	3.2	23
85	Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. <i>Journal of Urology</i> , 2021, 205, 1387-1393.	4.2	19
86	Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. <i>Journal of Endourology</i> , 2021, 35, 647-651.	2.8	10
87	The Economics of Cystoscopy: A Microcost Analysis. <i>Urology</i> , 2021, 157, 29-34.	1.4	20
88	Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. <i>Clinical Cancer Research</i> , 2021, 27, 5123-5130.	6.8	141
89	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	4.2	6
90	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	1.8	19

#	ARTICLE	IF	CITATIONS
91	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	2.3	41
92	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 409-421.	1.8	25
93	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.	2.1	26
94	A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2021, 7, 285-295.	0.5	6
95	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	2.3	4
96	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. <i>Cancers</i> , 2021, 13, 4378.	3.8	70
97	Same Day Discharge Versus Overnight Observation Protocols “ Similar Outcomes Following Artificial Urinary Sphincter Surgery. <i>Urology</i> , 2021, 157, 206-210.	1.4	7
98	Alternating Cystoscopy with Bladder EpiCheck ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.5	7
99	The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 206, 1380-1389.	4.2	16
100	A Multi-Institutional Phase 2 Trial of High-Dose SABR for Prostate Cancer Using Rectal Spacer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 101-109.	1.5	37
101	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 734.e11-734.e17.	1.8	6
102	Validation of testicular germ cell tumor staging in nationwide cancer registries. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 838.e1-838.e6.	1.8	4
103	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	5.8	96
104	Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study. <i>Cancers</i> , 2021, 13, 5935.	3.8	9
105	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology Oncology</i> , 2020, 3, 198-206.	5.8	12
106	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.8	34
107	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	1.8	9
108	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	1.8	21

#	ARTICLE	IF	CITATIONS
109	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	2.7	25
110	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 77, 583-598.	2.1	51
111	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e1-929.e10.	1.8	9
112	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	2.3	7
113	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e11-736.e18.	1.8	13
114	Initial Results from the M-STONE Group: A Multi-Center Collaboration to Study Treatment Outcomes in Nephrolithiasis Evaluation. <i>Journal of Endourology</i> , 2020, 34, 919-923.	2.8	7
115	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. <i>Cancer</i> , 2020, 126, 4362-4370.	4.0	23
116	Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. <i>World Journal of Urology</i> , 2020, 39, 1977-1984.	2.3	17
117	Office-Based Blue Light Flexible Cystoscopy Improves Diagnostic Capabilities. <i>Videourology (New)</i> Tj ETQq1 1 0.784314 rgBT ₀ /Overlo 0.1		
118	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 933.e7-933.e12.	1.8	16
119	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 737.e11-737.e16.	1.8	16
120	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.8	20
121	Novel technologies that change the diagnostic and treatment paradigm in urology. <i>Current Opinion in Urology</i> , 2020, 30, 477-478.	2.0	1
122	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17.	1.8	111
123	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1218.	2.5	8
124	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020, 3, 420-423.	5.8	37
125	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. <i>World Journal of Urology</i> , 2020, 39, 491-500.	2.3	5
126	A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging. <i>Journal of Urology</i> , 2020, 204, 239-246.	4.2	7

#	ARTICLE	IF	CITATIONS
127	Microhematuria: AUA/SUFU Guideline. <i>Journal of Urology</i> , 2020, 204, 778-786.	4.2	215
128	Implementation of a Urology E-Consult Service at a Safety Net County Hospital. <i>Urology Practice</i> , 2020, 7, 448-453.	1.3	6
129	Urinary-Based Markers for Bladder Cancer Detection. <i>Soci�t� Internationale D'urologie Journal</i> , 2020, 1, 49-61.	0.2	4
130	Clinical Utility of Bladder Cancer Biomarkers. <i>Soci�t� Internationale D'urologie Journal</i> , 2020, 1, 62-67.	0.2	3
131	Patient�reported outcomes of blue�light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. <i>BJU International</i> , 2019, 123, 35-41.	3.2	19
132	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1192.	2.5	18
133	Current advances in BCG-unresponsive non-muscle invasive bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 757-770.	3.9	27
134	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 758-764.	1.8	23
135	Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. <i>Trends in Cancer</i> , 2019, 5, 426-439.	10.4	75
136	DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. <i>Carcinogenesis</i> , 2019, 40, 1332-1340.	2.8	12
137	Evaluation of Hematuria in a Large Public Health Care System. <i>Bladder Cancer</i> , 2019, 5, 119-129.	0.5	31
138	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , 2019, 11, .	9.6	52
139	FP131COST ANALYSIS OF INCREASED WATER INTAKE ON RECURRENT CYSTITIS BASED ON RESULTS FROM A RANDOMIZED CLINICAL TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.8	0
140	Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. <i>European Urology Oncology</i> , 2019, 2, 691-698.	5.8	30
141	Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 158525.	2.4	18
142	Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. <i>European Urology</i> , 2019, 76, 238-243.	2.1	47
143	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. <i>European Urology</i> , 2019, 76, 200-206.	2.1	50
144	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA � update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	10.1	71

#	ARTICLE	IF	CITATIONS
145	Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3689-3701.	6.8	110
146	Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 478-484.	1.8	18
147	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	6.8	93
148	Recent advances in the metabolomic study of bladder cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 315-324.	2.0	36
149	Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. <i>International Journal of Molecular Sciences</i> , 2019, 20, 793.	4.4	29
150	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.3	11
151	Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. <i>European Urology Oncology</i> , 2019, 2, 397-404.	5.8	52
152	Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. <i>European Urology</i> , 2019, 75, 853-860.	2.1	85
153	Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate. <i>American Journal of Roentgenology</i> , 2019, 212, 576-581.	4.1	25
154	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62.	1.8	37
155	Validating the predictors of outcomes after radical cystectomy for bladder cancer. <i>Cancer</i> , 2019, 125, 223-231.	4.0	34
156	Effect of blue-light cystoscopy on contemporary performance of urine cytology. <i>BJU International</i> , 2019, 124, 251-257.	3.2	16
157	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 97-103.	3.5	4
158	Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. <i>European Urology Focus</i> , 2019, 5, 664-675.	3.5	5
159	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. <i>Oncogene</i> , 2019, 39, 6265-6285.	6.5	76
160	Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 1115-1120.	4.2	23
161	Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. <i>Journal of Urology</i> , 2019, 202, 920-926.	4.2	23
162	Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2019, 202, 1136-1142.	4.2	29

#	ARTICLE	IF	CITATIONS
163	Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI. <i>American Journal of Roentgenology</i> , 2018, 210, 1066-1072.	4.1	54
164	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 434-440.	3.2	16
165	Current approaches for identifying high-risk non-muscle invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 223-235.	2.5	7
166	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018, 199, 1158-1165.	4.2	93
167	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	1.4	20
168	Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 97-102.	1.8	10
169	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	1.8	29
170	Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial. <i>World Journal of Urology</i> , 2018, 36, 1441-1447.	2.3	12
171	Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures. <i>Urology Practice</i> , 2018, 5, 124-131.	1.3	2
172	Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. <i>European Urology Focus</i> , 2018, 4, 907-915.	3.5	56
173	Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15.	1.8	64
174	Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. <i>Journal of Urology</i> , 2018, 199, 655-662.	4.2	63
175	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 88.e11-88.e18.	1.8	16
176	Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e1-89.e5.	1.8	8
177	Natural history of second biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	3.2	14
178	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018, 74, 784-795.	2.1	693
179	Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections. <i>JAMA Internal Medicine</i> , 2018, 178, 1509.	10.5	242
180	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e21-500.e27.	1.8	0
182	Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 577-583.	2.0	16
183	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1221-e1235.	2.3	15
184	Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort. <i>World Journal of Urology</i> , 2018, 36, 1835-1843.	2.3	16
185	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. <i>European Urology Oncology</i> , 2018, 1, 242-251.	5.8	16
186	The Use of Blue Light Flexible Cystoscopy With Hexaminolevullinate & the Diagnosis of Bladder Cancer. <i>Future Oncology</i> , 2018, 14, 2805-2810.	2.3	3
187	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1981-1995.	2.3	125
188	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	1.8	4
189	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. <i>Cell Metabolism</i> , 2018, 28, 793-800.e2.	25.2	257
190	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. <i>European Urology Oncology</i> , 2018, 1, 223-230.	5.8	27
191	Molecular markers in bladder cancer. <i>World Journal of Urology</i> , 2018, 37, 31-40.	2.3	97
192	Editorial response to "Clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study". <i>Translational Cancer Research</i> , 2018, 7, S752-S754.	1.2	0
193	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. <i>BJU International</i> , 2017, 119, 234-238.	3.2	16
194	Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 612-620.	1.3	11
195	Decision Analysis Model Comparing Cost of Management Strategies for Pelvic Fracture Urethral Injuries. <i>Urology Practice</i> , 2017, 4, 285-289.	1.3	3
196	Guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2017, 119, 371-380.	3.2	248
197	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	33.0	693
198	Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma. <i>BJU International</i> , 2017, 119, 741-747.	3.2	16

#	ARTICLE	IF	CITATIONS
199	The economics of stone disease. <i>World Journal of Urology</i> , 2017, 35, 1321-1329.	2.3	41
200	Epidemiology of stone disease across the world. <i>World Journal of Urology</i> , 2017, 35, 1301-1320.	2.3	900
201	Bladder cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, .	47.2	740
202	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROIMPACT study. <i>Cancer</i> , 2017, 123, 2850-2859.	4.0	69
203	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2017, 198, 1021-1026.	4.2	5
204	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. <i>Journal of Urology</i> , 2017, 198, 552-559.	4.2	814
205	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	14.4	145
206	Lynch syndrome in upper tract urothelial carcinoma. <i>Current Opinion in Urology</i> , 2017, 27, 48-55.	2.0	34
207	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 689-695.e2.	2.3	14
208	Tackling non-muscle invasive bladder cancer in the clinic. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 467-480.	2.5	14
209	Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. <i>Scientific Reports</i> , 2017, 7, .	3.4	46
210	Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 531.e15-531.e22.	1.8	105
211	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. <i>Journal of Urology</i> , 2017, 197, 1419-1426.	4.2	103
212	An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer—Preliminary experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 149.e15-149.e21.	1.8	24
213	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	33.7	2,166
214	Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260.	0.9	22
215	Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e17-660.e25.	1.8	5
216	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1039-e1045.	2.3	15

#	ARTICLE	IF	CITATIONS
217	Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2017, 6, 2106-2120.	2.6	65
218	Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. <i>Medical Dosimetry</i> , 2017, 42, 341-347.	0.9	30
219	Editorial comment. <i>Current Opinion in Urology</i> , 2017, 27, 34.	2.0	0
220	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2017, 198, 1269-1277.	4.2	5
221	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	4.2	64
222	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	4.2	41
223	Superior Cost Effectiveness of Penile Plication vs Intralesional Collagenase Injection for Treatment of Peyronie's Disease Deformities. <i>Urology Practice</i> , 2017, 4, 118-125.	1.3	23
224	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. <i>Journal of Urology</i> , 2017, 197, 1208-1213.	4.2	60
225	Prevention of Recurrent Acute Uncomplicated Cystitis by Increasing Daily Water in Premenopausal Women: A Prospective, Randomized, Controlled Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S736-S736.	0.8	5
226	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	2.7	15
227	Alternative therapies in patients with non-muscle invasive bladder cancer. <i>Turkish Journal of Urology</i> , 2017, 43, 414-424.	0.2	8
228	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.5	8
229	Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. <i>BJU International</i> , 2016, 117, 783-786.	3.2	91
230	Long-term outcomes in a high-risk bladder cancer screening cohort. <i>BJU International</i> , 2016, 117, 611-617.	3.2	20
231	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , 2016, 118, 243-249.	3.2	14
232	Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. <i>Journal of Endourology</i> , 2016, 30, S-28-S-33.	2.8	18
233	Analysis of genetics to identify susceptibility to secondary malignancies in patients with bladder cancer. <i>BJU International</i> , 2016, 118, 12-13.	3.2	1
234	Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 418.e9-418.e16.	1.8	14

#	ARTICLE	IF	CITATIONS
235	Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial. <i>European Journal of Cancer</i> , 2016, 59, 142-151.	4.9	141
236	Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e19-291.e26.	1.8	32
237	Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. <i>Cancer</i> , 2016, 122, 3785-3793.	4.0	25
238	Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. <i>Urology</i> , 2016, 96, 44-53.	1.4	15
239	Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1189-1199.	3.0	10
240	Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 531.e1-531.e6.	1.8	32
241	Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 417.e1-417.e8.	1.8	15
242	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e7-485.e14.	1.8	20
243	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2016, 196, 1627-1633.	4.2	39
244	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. <i>Urology</i> , 2016, 94, 314.e1-314.e7.	1.4	16
245	Bladder cancer. <i>Lancet, The</i> , 2016, 388, 2796-2810.	62.3	1,325
246	Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 255.e7-255.e13.	1.8	40
247	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. <i>EBioMedicine</i> , 2016, 7, 85-93.	9.7	6
248	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016, 2, 79-85.	3.5	44
249	Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 416.e9-416.e14.	1.8	33
250	Should patients newly diagnosed with bladder cancer be screened for lung cancer?. <i>International Journal of Urology</i> , 2016, 23, 346-347.	1.6	4
251	Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. <i>Journal of Urology</i> , 2016, 195, 1911-1919.	4.2	36
252	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e9-167.e16.	1.8	29

#	ARTICLE	IF	CITATIONS
253	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e1-233.e6.	1.8	25
254	Use of an Electronic Medical Record to Assess Patient-Reported Morbidity Following Ureteroscopy. <i>Journal of Endourology</i> , 2016, 30, S-46-S-51.	2.8	14
255	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2016, 196, 321-326.	4.2	17
256	The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 296-302.	1.8	25
257	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 47-62.	2.0	77
258	Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 105-118.	2.0	13
259	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?. <i>Journal of Urology</i> , 2016, 195, 886-893.	4.2	77
260	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. <i>European Urology</i> , 2016, 69, 300-310.	2.1	596
261	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 53-59.	4.2	105
262	Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 80-87.	4.2	30
263	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2016, 35, 251-259.	2.3	47
264	Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2016, 35, 105-111.	2.3	8
265	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2016, 35, 113-120.	2.3	27
266	The kidney stone and increased water intake trial in steel workers: results from a pilot study. <i>Urolithiasis</i> , 2016, 45, 177-183.	1.8	26
267	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2016, 35, 379-387.	2.3	385
268	Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2015, 17, 713-719.	2.0	25
269	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 268.e1-268.e7.	1.8	30
270	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. <i>Journal of Urology</i> , 2015, 194, 21-29.	4.2	71

#	ARTICLE	IF	CITATIONS
271	We Should Screen Smokers for Bladder and Kidney Cancer. <i>European Urology Focus</i> , 2015, 1, 50-51.	3.5	1
272	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	2.1	278
273	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	2.1	90
274	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 677-682.	1.1	19
275	Utility of Biomarkers in the Prediction of Oncologic Outcome after Radical Cystectomy for Squamous Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 451-456.	4.2	15
276	Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2015, 121, 43-50.	4.0	22
277	Promises and challenges of fluorescence cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 261-264.	1.8	11
278	Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2015, 85, 876-882.	1.4	28
279	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e21-71.e26.	1.8	27
280	Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 65.e19-65.e25.	1.8	50
281	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	1.8	12
282	Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 111.e1-111.e7.	1.8	8
283	Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 266.e9-266.e16.	1.8	32
284	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e15-495.e22.	1.8	15
285	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. <i>Urology</i> , 2015, 86, 1146-1152.	1.4	27
286	ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. <i>Cancer Research</i> , 2015, 75, 5155-5166.	3.8	66
287	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, .	1.5	14
288	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	2.3	9

#	ARTICLE	IF	CITATIONS
289	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	4.2	43
290	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e21-18.e26.	1.8	8

291

#	ARTICLE	IF	CITATIONS
307	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677.	4.2	24
308	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. <i>Urology</i> , 2014, 83, 863-868.	1.4	91
309	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	4.2	39
310	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e7-49.e14.	1.8	42
311	Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2014, 65, 201-209.	2.1	38
312	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	1.8	31
313	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 625-630.	1.8	25
314	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. <i>European Urology</i> , 2014, 66, 913-919.	2.1	113
315	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	2.1	162
316	What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 128-134.	1.8	60
317	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	1.8	35
318	The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. <i>European Urology</i> , 2014, 66, 253-262.	2.1	502
319	Urine markers for detection and surveillance of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 222-229.	1.8	97
320	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	2.1	29
321	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988.	1.8	49
322	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.4	18
323	Electrophysiological analysis of biopsy samples using elasticity as an inherent cell marker for cancer detection. <i>Analytical Methods</i> , 2014, 6, 7166-7174.	2.5	23
324	Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in 2030. <i>European Urology</i> , 2014, 66, 724-729.	2.1	320

#	ARTICLE	IF	CITATIONS
325	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. <i>European Urology</i> , 2014, 66, 439-446.	2.1	24
326	Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1238-1243.	4.2	28
327	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	2.1	143
328	Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e17-37.e23.	1.8	22
329	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	1.8	33
330	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e1-47.e8.	1.8	8
331	Prospective External Validation of a Bladder Cancer Detection Model. <i>Journal of Urology</i> , 2014, 192, 1343-1348.	4.2	35
332	Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 509-517.	1.5	186
333	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	4.2	72
334	Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 65, 316-324.	2.1	91
335	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	2.1	228
336	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2014, 33, 1165-1171.	2.3	21
337	Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?. <i>World Journal of Urology</i> , 2014, 33, 1309-1313.	2.3	43
338	Spectrum of diverse genomic alterations define non-“clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2014, 47, 13-21.	25.2	339
339	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. <i>BJU International</i> , 2013, 111, 249-255.	3.2	74
340	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , 2013, 111, 74-84.	3.2	29
341	Systematic Review of Complications of Prostate Biopsy. <i>European Urology</i> , 2013, 64, 876-892.	2.1	948
342	Metabolomic signatures of aggressive prostate cancer. <i>Prostate</i> , 2013, 73, 1547-1560.	2.1	123

#	ARTICLE	IF	CITATIONS
343	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	33.7	291
344	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 480-486.	1.8	36
345	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	4.2	43
346	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 812-826.	1.8	7
347	Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2013, 112, 1105-1112.	3.2	69
348	Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1662-1667.	4.2	25
349	Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2013, 81, 581-586.	1.4	41
350	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. <i>European Urology</i> , 2013, 63, 371-378.	2.1	53
351	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.	2.1	236
352	Epidemiology and Risk Factors of Urothelial Bladder Cancer. <i>European Urology</i> , 2013, 63, 234-241.	2.1	1,859
353	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, .	3.2	79
354	Reduction in Hospital Admission Rates Due to Post-Prostate Biopsy Infections After Augmenting Standard Antibiotic Prophylaxis. <i>Journal of Urology</i> , 2013, 189, 535-540.	4.2	87
355	Impact of Statin Use on Oncologic Outcomes in Patients with Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Journal of Urology</i> , 2013, 190, 487-492.	4.2	35
356	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1082-1090.	2.1	117
357	Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 676-681.	1.8	4
358	Cost-Effectiveness of Fluorescence In Situ Hybridization in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1181-1186.	4.2	38
359	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	4.9	167
360	How Much is a Kidney Worth? Cost-Effectiveness of Routine Imaging After Ureteroscopy to Prevent Silent Obstruction. <i>Journal of Urology</i> , 2013, 189, 2136-2141.	4.2	24

#	ARTICLE	IF	CITATIONS
361	Summary of the 6th annual bladder cancer think tank: New directions in urologic research. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 968-973.	1.8	6
362	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. European Urology, 2013, 64, 456-464.	2.1	113
363	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. European Urology, 2013, 64, 837-845.	2.1	71
364	Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma. Urology, 2013, 81, 972-978.	1.4	66
365	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. European Urology, 2013, 63, 724-732.	2.1	120
366	Obesity is Associated with Worse Outcomes in Patients with T1 High Grade Urothelial Carcinoma of the Bladder. Journal of Urology, 2013, 190, 480-486.	4.2	75
367	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. Journal of Urology, 2013, 189, 1662-1669.	4.2	161
368	Urinary cytology for the detection of urothelial carcinoma of the bladder—a flawed adjunct to cystoscopy?. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 366-371.	1.8	15
369	Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. BJU International, 2013, 111, 1054-1060.	3.2	39
370	Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. European Urology, 2013, 63, 1049-1058.	2.1	71
371	Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. European Urology, 2013, 64, 465-471.	2.1	71
372	Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU International, 2013, 112, .	3.2	28
373	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 904-908.	1.8	88
374	Impact of fluid intake in the prevention of urinary system diseases. Current Opinion in Nephrology and Hypertension, 2013, 22, S1-S10.	2.2	65
375	Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?. BJU International, 2013, 112, 1053-1254.	3.2	2
376	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	3.2	36
377	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. BJU International, 2013, 112, 453-461.	3.2	146
378	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU International, 2013, 111, 1215-1221.	3.2	61

#	ARTICLE	IF	CITATIONS
379	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 614-621.	2.1	10
380	Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. <i>International Archives of Occupational and Environmental Health</i> , 2013, 87, 715-724.	2.0	59
381	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e31s-e37s.	2.9	87
382	Is robotic surgery cost-effective. <i>Current Opinion in Urology</i> , 2012, 22, 66-69.	2.0	52
383	A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, .	12.5	169
384	Cost Comparison of Robot-Assisted and Laparoscopic Pyeloplasty. <i>Journal of Endourology</i> , 2012, 26, 1044-1048.	2.8	27
385	High-Grade Ureteroscopic Biopsy Is Associated with Advanced Pathology of Upper-Tract Urothelial Carcinoma Tumors at Definitive Surgical Resection. <i>Journal of Endourology</i> , 2012, 26, 398-402.	2.8	78
386	Three differentiation states risk-stratify bladder cancer into distinct subtypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2078-2083.	7.5	251
387	BAP1 loss defines a new class of renal cell carcinoma. <i>Nature Genetics</i> , 2012, 44, 751-759.	25.2	870
388	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. <i>International Journal of Urology</i> , 2012, 19, 1060-1066.	1.6	67
389	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	2.3	20
390	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. <i>European Urology</i> , 2012, 62, 677-684.	2.1	101
391	Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. <i>Journal of Urology</i> , 2012, 187, 457-462.	4.2	43
392	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 187, 845-851.	4.2	62
393	Evaluation of Vitamin E and Selenium Supplementation for the Prevention of Bladder Cancer in SWOG Coordinated SELECT. <i>Journal of Urology</i> , 2012, 187, 2005-2010.	4.2	44
394	12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 944-947.	1.8	4
395	Residual Fragments Following Ureteroscopic Lithotripsy: Incidence and Predictors on Postoperative Computerized Tomography. <i>Journal of Urology</i> , 2012, 188, 2246-2251.	4.2	80
396	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2120-2128.	4.2	50

#	ARTICLE	IF	CITATIONS
397	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	2.3	58
398	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 252-258.	1.8	95
399	Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 273-277.	1.8	31
400	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 188, 398-404.	4.2	135
401	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. <i>Current Urology Reports</i> , 2012, 13, 122-135.	2.5	51
402	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. <i>European Urology</i> , 2012, 61, 245-253.	2.1	175
403	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	2.1	74
404	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 818-825.	2.1	201
405	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. <i>BJU International</i> , 2012, 109, 685-690.	3.2	30
406	Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis. <i>BJU International</i> , 2012, 110, .	3.2	44
407	Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. <i>BJU International</i> , 2012, 110, 961-966.	3.2	12
408	Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. <i>BJU International</i> , 2012, 110, 967-972.	3.2	28
409	Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. <i>BJU International</i> , 2012, 110, .	3.2	63
410	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. <i>World Journal of Urology</i> , 2012, 31, 1029-1036.	2.3	64
411	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2012, 31, 5-11.	2.3	41
412	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2012, 20, 1027-1034.	2.3	27
413	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011, 108, 687-692.	3.2	32
414	Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2011, 185, 1112-1117.	4.2	7

#	ARTICLE	IF	CITATIONS
415	Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy. <i>Journal of Urology</i> , 2011, 185, 1216-1221.	4.2	34
416	Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2011, 185, 456-461.	4.2	90
417	Cost Comparison of Robotic, Laparoscopic, and Open Partial Nephrectomy. <i>Journal of Endourology</i> , 2011, 25, 447-453.	2.8	113
418	Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. <i>Cancer Research</i> , 2011, 71, 7376-7386.	3.8	189
419	Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder†. <i>Human Pathology</i> , 2011, 42, 347-355.	2.3	22
420	Editorial Comment. <i>Urology</i> , 2011, 77, 159.	1.4	0
421	Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2011, 77, 861-866.	1.4	35
422	Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 27-32.	1.8	80
423	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 716-723.	1.8	80
424	Predictors of costs for robotic-assisted laparoscopic radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 325-329.	1.8	16
425	Practice Variation in the Surgical Management of Urinary Lithiasis. <i>Journal of Urology</i> , 2011, 186, 146-150.	4.2	68
426	Obesity Adversely Impacts Disease Specific Outcomes in Patients With Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2011, 186, 66-72.	4.2	62
427	Cost-Effectiveness of Primary Prevention Strategies for Nephrolithiasis. <i>Journal of Urology</i> , 2011, 186, 550-555.	4.2	36
428	Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011, 37, 706-711.	2.1	3
429	Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer. <i>Scientific World Journal</i> , The, 2011, 11, 369-381.	9.7	74
430	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , 2011, 108, 24-30.	3.2	115
431	Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. <i>BJU International</i> , 2011, 108, 31-37.	3.2	25
432	Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. <i>BJU International</i> , 2011, 108, 701-705.	3.2	230

#	ARTICLE	IF	CITATIONS
433	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2011, 108, 1286-1291.	3.2	74
434	Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non-Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 59, 1026-1031.	2.1	57
435	Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. <i>European Urology</i> , 2011, 60, 776-783.	2.1	146
436	Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2011, 117, 276-282.	4.0	138
437	Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1483-1491.	1.1	152
438	Primary Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Pathology</i> , 2011, 135, 822-830.	0.7	21
439	Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an Elevated Prostate Specific Antigen. <i>Cancer Prevention Research</i> , 2011, 4, 277-283.	1.5	11
440	Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2011, 9, 1255-1265.	3.1	106
441	Cost-effectiveness of robotic-assisted laparoscopic procedures in urologic surgery in the USA. <i>Expert Review of Medical Devices</i> , 2011, 8, 97-103.	2.0	23
442	The Impact of Previous Ureteroscopic Tumor Ablation on Oncologic Outcomes After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Endourology</i> , 2011, 25, 775-779.	2.8	22
443	Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. <i>World Journal of Urology</i> , 2011, 30, 785-794.	2.3	11
444	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. <i>World Journal of Urology</i> , 2011, 30, 753-759.	2.3	34
445	Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. <i>BJU International</i> , 2010, 105, 1672-1677.	3.2	120
446	Economics of robotics in urology. <i>Current Opinion in Urology</i> , 2010, 20, 92-97.	2.0	39
447	The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. <i>BJU International</i> , 2010, 105, 1531-1535.	3.2	40
448	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. <i>European Urology</i> , 2010, 57, 1072-1079.	2.1	167
449	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. <i>European Urology</i> , 2010, 57, 300-309.	2.1	174
450	Cost Comparison of Robotic, Laparoscopic, and Open Radical Prostatectomy for Prostate Cancer. <i>European Urology</i> , 2010, 57, 453-458.	2.1	258

#	ARTICLE	IF	CITATIONS
451	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. <i>European Urology</i> , 2010, 58, 112-117.	2.1	55
452	High-risk patients with hematuria are not evaluated according to guideline recommendations. <i>Cancer</i> , 2010, 116, 2954-2959.	4.0	75
453	p53 expression in patients with advanced urothelial cancer of the urinary bladder. <i>BJU International</i> , 2010, 105, 489-495.	3.2	69
454	A delay in radical nephroureterectomy can lead to upstaging. <i>BJU International</i> , 2010, 105, 812-817.	3.2	92
455	Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. <i>BJU International</i> , 2010, 106, 1216-1222.	3.2	84
456	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010, 105, 1402-1412.	3.2	138
457	The influence of body mass index on the cost of radical prostatectomy for prostate cancer. <i>BJU International</i> , 2010, 106, 1188-1193.	3.2	12
458	Transitional research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers. <i>Cancer Biology and Therapy</i> , 2010, 10, 407-415.	4.1	22
459	Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients. <i>Journal of Urology</i> , 2010, 183, 87-93.	4.2	60
460	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 68-75.	4.2	151
461	Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management. <i>Journal of Urology</i> , 2010, 183, 188-193.	4.2	63
462	Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2010, 183, 62-67.	4.2	100
463	Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. <i>Journal of Urology</i> , 2010, 184, 888-894.	4.2	68
464	Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2010, 184, 69-73.	4.2	234
465	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. <i>Journal of Urology</i> , 2010, 183, 2165-2170.	4.2	187
466	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2010, 184, 453-458.	4.2	193
467	pT3 Substaging is a Prognostic Indicator for Lymph Node Negative Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2010, 184, 470-474.	4.2	32
468	Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 500-503.	1.8	84

#	ARTICLE	IF	CITATIONS
469	Role of biomarkers to predict outcomes and response to therapy. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 97-101.	1.8	7
470	BCAN Think Tank session 2: Molecular detection of bladder cancer: The path to progress. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 334-337.	1.8	4
471	Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 441-448.	1.8	94
472	Statistical consideration for clinical biomarker research in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 389-400.	1.8	124
473	Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival. BJU International, 2010, 106, 1324-1329.	3.2	34
474	Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. Journal of Urology, 2010, 183, 1744-1750.	4.2	95
475	Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 Patients. Journal of Urology, 2010, 183, 1757-1763.	4.2	72
476	Mesh kits for anterior vaginal prolapse are not cost effective. International Urogynecology Journal, 2010, 22, 447-452.	1.5	12
477	Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. Urological Research, 2010, 39, 141-146.	0.4	52
478	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. Journal of the National Cancer Institute, 2009, 101, 114-119.	4.6	149
479	Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. Clinical Cancer Research, 2009, 15, 7012-7019.	6.8	70
480	Prostate cancer biomarker discovery using high performance mass spectral serum profiling. Computer Methods and Programs in Biomedicine, 2009, 96, 33-41.	4.6	18
481	Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients. European Urology, 2009, 55, 1124-1134.	2.1	60
482	Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. European Urology, 2009, 56, 430-442.	2.1	664
483	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009, 115, 1224-1233.	4.0	1,053
484	Key concerns about the current state of bladder cancer. Cancer, 2009, 115, 4096-4103.	4.0	72
485	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph node density. BJU International, 2009, 103, 302-306.	3.2	95
486	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU International, 2009, 103, 307-311.	3.2	169

#	ARTICLE	IF	CITATIONS
487	Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. <i>BJU International</i> , 2009, 103, 1359-1362.	3.2	78
488	Impact of body mass index on clinical and cost outcomes after radical cystectomy. <i>BJU International</i> , 2009, 104, 326-330.	3.2	20
489	Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. <i>BJU International</i> , 2009, 103, 1368-1374.	3.2	62
490	Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome. <i>BJU International</i> , 2009, 104, 786-789.	3.2	40
491	Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. <i>Urology</i> , 2009, 73, 142-146.	1.4	77
492	General Anesthesia and Contrast-Enhanced Computed Tomography to Optimize Renal Percutaneous Radiofrequency Ablation: Multi-Institutional Intermediate-Term Results. <i>Journal of Endourology</i> , 2009, 23, 1099-1105.	2.8	64
493	Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement. <i>Journal of Urology</i> , 2009, 181, 149-153.	4.2	41
494	Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy. <i>Journal of Urology</i> , 2009, 182, 586-590.	4.2	42
495	Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 78-84.	4.2	94
496	Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker. <i>Journal of Urology</i> , 2009, 182, 52-58.	4.2	79
497	p53 Predictive Value for pT1-2 NO Disease at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 907-913.	4.2	54
498	Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2NO Bladder Cancer. <i>Journal of Urology</i> , 2009, 182, 459-465.	4.2	18
499	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. <i>Journal of Urology</i> , 2009, 181, 2482-2489.	4.2	197
500	How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease. <i>Journal of Urology</i> , 2009, 182, 998-1004.	4.2	37
501	Economics and Cost of Care of Stone Disease. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 5-10.	1.8	141
502	Natural History of Residual Fragments Following Percutaneous Nephrostolithotomy. <i>Journal of Urology</i> , 2009, 181, 1163-1168.	4.2	195
503	Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. <i>BJU International</i> , 2008, .	3.2	21
504	Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. <i>BJU International</i> , 2008, .	3.2	29

#	ARTICLE	IF	CITATIONS
505	Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours. BJU International, 2008, .	3.2	35
506	Is there a rationale for bladder cancer screening?. Current Urology Reports, 2008, 9, 339-341.	2.5	6
507	Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 2008, 112, 315-325.	4.0	187
508	Cost-effectiveness of prostate cancer chemoprevention. Cancer, 2008, 112, 1058-1065.	4.0	62
509	The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses. Cancer, 2008, 113, 2681-2686.	4.0	21
510	Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU International, 2008, 101, 561-565.	3.2	27
511	Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU International, 2008, 101, 1362-1367.	3.2	35
512	Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU International, 2008, 101, 1356-1361.	3.2	19
513	Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU International, 2008, 102, 172-176.	3.2	80
514	Predicting survival after radical cystectomy for bladder cancer. BJU International, 2008, 102, 15-22.	3.2	49
515	Urothelial bladder cancer: biomarkers for detection and screening. BJU International, 2008, 102, 1234-1241.	3.2	20
516	Cost-Effectiveness of Medical Expulsive Therapy Using Alpha-Blockers for the Treatment of Distal Ureteral Stones. European Urology, 2008, 53, 411-419.	2.1	109
517	Nomograms for Bladder Cancer. European Urology, 2008, 54, 41-53.	2.1	93
518	Outcomes of Patients with Clinical T1 Grade 3 Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy. Urology, 2008, 71, 302-307.	1.4	64
519	Are Urologists Fairly Reimbursed for Complex Procedures: Failure of 22 Modifier?. Urology, 2008, 72, 494-497.	1.4	19
520	Impact of Body Mass Index on Cost and Clinical Outcomes After Percutaneous Nephrostolithotomy. Urology, 2008, 72, 756-760.	1.4	65
521	Determinants of Quality of Life for Patients With Kidney Stones. Journal of Urology, 2008, 179, 2238-2243.	4.2	118
522	Does Obesity Impact the Costs of Partial and Radical Nephrectomy?. Journal of Urology, 2008, 179, 1714-1718.	4.2	14

#	ARTICLE	IF	CITATIONS
523	Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 179, 2164-2169.	4.2	77
524	Climate-related increase in the prevalence of urolithiasis in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9841-9846.	7.5	341
525	Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1401-1411.	4.6	68
526	Sirolimus in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3457-3460.	16.9	14
527	Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. <i>Nature Reviews Urology</i> , 2008, 5, 676-685.	5.1	33
528	Costâ€ effectiveness of bladder cancer screening. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 627-632.	1.4	2
529	Bladder Cancer Screening and Future Directions in Urine-Based Markers for Bladder Urothelial Carcinoma. <i>Laboratory Medicine</i> , 2007, 38, 116-120.	1.0	0
530	Laparoscopic and Open Partial Nephrectomy: Cost Comparison with Analysis of Individual Parameters. <i>Journal of Endourology</i> , 2007, 21, 1449-1454.	2.8	15
531	Urine Cytology and Commercially Available Urine-Based Markers for Monitoring of Bladder Urothelial Carcinoma. <i>Laboratory Medicine</i> , 2007, 38, 48-52.	1.0	1
532	Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualifies for Bladder Preservation Protocols?. <i>Current Urology</i> , 2007, 1, 24-27.	0.9	0
533	Contemporary Laparoscopic and Open Radical Retropubic Prostatectomy: Pathologic Outcomes and Kattan Postoperative Nomograms Are Equivalent. <i>Urology</i> , 2007, 69, 118-122.	1.4	8
534	In Vitro Assessment of the Efficacy of Thermal Therapy in Human Renal Cell Carcinoma. <i>Urology</i> , 2007, 70, 380-384.	1.4	25
535	Survivin Expression in Patients with Non-Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. <i>Urology</i> , 2007, 70, 482-486.	1.4	55
536	Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 291-297.	1.8	31
537	Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 468-475.	1.8	45
538	Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. <i>Human Pathology</i> , 2007, 38, 1703-1713.	2.3	77
539	Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. <i>Lancet Oncology</i> , The, 2007, 8, 128-136.	27.4	204
540	Efficacy of Laser-Activated Gold Nanoshells in Ablating Prostate Cancer Cells in Vitro. <i>Journal of Endourology</i> , 2007, 21, 939-943.	2.8	112

#	ARTICLE	IF	CITATIONS
541	Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma. <i>Journal of Urology</i> , 2007, 177, 481-487.	4.2	134
542	Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder. <i>Journal of Urology</i> , 2007, 177, 1163-1168.	4.2	46
543	Economics of Stone Management. <i>Urologic Clinics of North America</i> , 2007, 34, 443-453.	2.0	65
544	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. <i>Cancer</i> , 2007, 109, 1106-1113.	4.0	143
545	Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. <i>Prostate</i> , 2007, 67, 614-622.	2.1	134
546	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. <i>Modern Pathology</i> , 2007, 20, 445-459.	4.8	128
547	Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. <i>BJU International</i> , 2007, 100, 287-290.	3.2	136
548	A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. <i>BJU International</i> , 2007, 100, 1015-1020.	3.2	59
549	Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy. <i>European Urology</i> , 2007, 51, 137-151.	2.1	332
550	Concomitant Carcinoma In Situ Is a Feature of Aggressive Disease in Patients With Organ-Confined TCC at Radical Cystectomy. <i>European Urology</i> , 2007, 51, 152-160.	2.1	80
551	Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2007, 51, 699-708.	2.1	160
552	Survivin: a promising biomarker for detection and prognosis of bladder cancer. <i>World Journal of Urology</i> , 2007, 26, 59-65.	2.3	94
553	Screening for bladder cancer: a perspective. <i>World Journal of Urology</i> , 2007, 26, 13-18.	2.3	50
554	Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium. <i>Journal of Urology</i> , 2006, 176, 2414-2422.	4.2	650
555	Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer. <i>Journal of Urology</i> , 2006, 176, 919-926.	4.2	103
556	Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 176, 1354-1362.	4.2	195
557	Nicotinamide Adenine Dinucleotide Staining Immediately Following Radio Frequency Ablation of Renal Tumors Is a Positive Stain Synonymous With Ablative Failure?. <i>Journal of Urology</i> , 2006, 176, 1969-1972.	4.2	29
558	Cancer Specific Outcomes in Patients With PTO Disease Following Radical Cystectomy. <i>Journal of Urology</i> , 2006, 175, 1645-1649.	4.2	50

#	ARTICLE	IF	CITATIONS
559	Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model. <i>Journal of Urology</i> , 2006, 175, 1932-1936.	4.2	28
560	Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 175, 2048-2053.	4.2	169
561	Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. <i>Human Pathology</i> , 2006, 37, 1568-1576.	2.3	91
562	Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. <i>Urology</i> , 2006, 68, 538-542.	1.4	31
563	Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 338-343.	1.8	45
564	Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 561-562.	1.8	3
565	Novel blood biomarkers of human urinary bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 562-563.	1.8	2
566	A survivin gene signature predicts aggressive tumor behavior. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 563-564.	1.8	0
567	Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer. <i>Laboratory Medicine</i> , 2006, 37, 429-435.	1.0	0
568	Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model. <i>European Urology</i> , 2006, 50, 795-800.	2.1	77
569	Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. <i>European Urology</i> , 2006, 50, 1254-1262.	2.1	152
570	Soluble Fas [®] A promising novel urinary marker for the detection of recurrent superficial bladder cancer. <i>Cancer</i> , 2006, 106, 1701-1707.	4.0	57
571	Should we screen for bladder cancer in a high-risk population?. <i>Cancer</i> , 2006, 107, 982-990.	4.0	126
572	Radiofrequency Ablation of Renal Tumors: Intermediate-Term Results. <i>Journal of Endourology</i> , 2006, 20, 569-573.	2.8	137
573	The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1485-1489.	1.1	30
574	The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. <i>BJU International</i> , 2005, 95, 977-981.	3.2	44
575	A cost comparison of nephron-sparing surgical techniques for renal tumour. <i>BJU International</i> , 2005, 95, 1039-1042.	3.2	61
576	International comparison of cost effectiveness of medical management strategies for nephrolithiasis. <i>Urological Research</i> , 2005, 33, 223-230.	0.4	75

#	ARTICLE	IF	CITATIONS
577	Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2005, 23, 1911-1920.	16.9	34
578	Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6533-6539.	16.9	305
579	NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2005, 173, 1518-1525.	4.2	157
580	Economics of Stone Management. <i>EAU Update Series</i> , 2005, 3, 51-60.	1.0	3
581	Conservative management of priapism in acute spinal cord injury. <i>Urology</i> , 2005, 65, 1195-1197.	1.4	24
582	Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. <i>Urology</i> , 2005, 66, 65-68.	1.4	32
583	Cost comparison of laparoscopic versus radical retropubic prostatectomy. <i>Urology</i> , 2005, 66, 557-560.	1.4	41
584	Survivin expression is associated with features of biologically aggressive prostate carcinoma. <i>Cancer</i> , 2004, 100, 751-757.	4.0	161
585	THE PERCENT OF BIOPSY CORES POSITIVE FOR CANCER IS A PREDICTOR OF ADVANCED PATHOLOGICAL STAGE AND POOR CLINICAL OUTCOMES IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2004, 171, 2209-2214.	4.2	45
586	COST-EFFECTIVENESS OF MEDICAL MANAGEMENT STRATEGIES FOR NEPHROLITHIASIS. <i>Journal of Urology</i> , 2004, 172, 2275-2281.	4.2	94
587	THE VALUE OF YOUR TIME: EVALUATION OF EFFECTS OF CHANGES IN MEDICARE REIMBURSEMENT RATES ON THE PRACTICE OF UROLOGY. <i>Journal of Urology</i> , 2004, 172, 1958-1962.	4.2	51
588	THE NEW ECONOMICS OF RADICAL PROSTATECTOMY: COST COMPARISON OF OPEN, LAPAROSCOPIC AND ROBOT ASSISTED TECHNIQUES. <i>Journal of Urology</i> , 2004, 172, 1431-1435.	4.2	268
589	Cost-Effective Treatment for Ureteropelvic Junction Obstruction: A Decision Tree Analysis. <i>Journal of Urology</i> , 2003, 169, 228-232.	4.2	30
590	Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. <i>Urology</i> , 2003, 61, 109-118.	1.4	456
591	Histopathology of surgically managed renal tumors: analysis of a contemporary series. <i>Urology</i> , 2003, 62, 827-830.	1.4	161
592	Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. <i>Urology</i> , 2003, 62, 918-921.	1.4	111
593	Cost Comparison of Hand Assisted Laparoscopic Nephrectomy and Open Nephrectomy: Analysis of Individual Parameters. <i>Journal of Urology</i> , 2003, 170, 752-755.	4.2	24
594	Cost-Effective Treatment for Ureteropelvic Junction Obstruction: A Decision Tree Analysis. <i>Journal of Urology</i> , 2003, , 228-232.	4.2	5

#	ARTICLE	IF	CITATIONS
595	Clinical Use of the Holmium:YAG Laser in Laparoscopic Partial Nephrectomy. Journal of Endourology, 2002, 16, 289-292.	2.8	70
596	Radiofrequency Coagulation of Renal Parenchyma: Comparison of Effects of Energy Generators on Treatment Efficacy. Journal of Endourology, 2002, 16, 83-88.	2.8	46
597	Laparoscopic Interstitial Laser Coagulation of Renal Tissue with and without Hilar Occlusion in the Porcine Model. Journal of Endourology, 2002, 16, 565-570.	2.8	19
598	Laparoscopic Partial Nephrectomy with a Diode Laser: Porcine Results. Journal of Endourology, 2002, 16, 749-753.	2.8	46
599	Transvaginal laparoscopic nephrectomy: development and feasibility in the porcine model. Urology, 2002, 59, 446-450.	1.4	251
600	Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters. Urology, 2002, 59, 821-825.	1.4	33
601	Laparoscopic Versus Open Retroperitoneal Lymph Node Dissection: a Cost Analysis. Journal of Urology, 2002, 168, 1945-1949.	4.2	26
602	Management Of Ureteral Calculi: A Cost Comparison And Decision Making Analysis. Journal of Urology, 2002, 167, 1621-1629.	4.2	183
603	COST-EFFECTIVENESS OF A MODIFIED CARE PROTOCOL SUBSTITUTING BLADDER TUMOR MARKERS FOR CYSTOSCOPY FOR THE FOLLOWUP OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A DECISION ANALYTICAL APPROACH. Journal of Urology, 2002, 167, 75-79.	4.2	97
604	COST-EFFECTIVENESS OF A MODIFIED CARE PROTOCOL SUBSTITUTING BLADDER TUMOR MARKERS FOR CYSTOSCOPY FOR THE FOLLOWUP OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER:. Journal of Urology, 2002, , 75-79.	4.2	4
605	Management Of Ureteral Calculi: A Cost Comparison And Decision Making Analysis. Journal of Urology, 2002, , 1621-1629.	4.2	7
606	Laparoscopic Versus Open Retroperitoneal Lymph Node Dissection: a Cost Analysis. Journal of Urology, 2002, , 1945-1949.	4.2	5
607	Implementing Blue Light Flexible Cystoscopy in Non-Muscle Invasive Bladder Cancer Surveillance. European Medical Journal Urology, 0, , 2-10.	0.0	1
608	Impact of timing of computed tomography staging and patient factors on the detection of â€^{TM} bladder cancer. BJU International, 0, 136, 911-919.	3.2	0
609	Assessing the Diagnostic Performance of Renal Ultrasound in Microhematuria Evaluation: Validation of the AUA Microhematuria 2020 Guidelines. Urology, 0, 207, 196-200.	1.4	2
610	Cost-effectiveness Analysis of Treatments for Bacillus Calmette-GuÃ©rinâ€“unresponsive Carcinoma in Situ of the Bladder. European Urology, 0, 89, 151-162.	2.1	2
611	Erdafitinib in Patients with High- and Intermediate-risk Nonâ€“muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology, 0, 89, 165-173.	2.1	0
612	Intermediate-risk Nonâ€“muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. European Urology Oncology, 0, 8, 1685-1695.	5.8	1

#	ARTICLE	IF	CITATIONS
613	Guidance for avoiding patient pain and discomfort during transurethral cystoscopy. Expert Review of Medical Devices, 0, 22, 1361-1367.	2.0	0
614	The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review. Oncology and Therapy, 0, 13, 895-918.	2.6	0
615	Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 0, 44, 274-285.	16.9	0
616	Impact of insurance status on testicular cancer outcomes: A single-institution, dual-site study. Urologic Oncology: Seminars and Original Investigations, 0, , 110969.	1.8	1